ASTRAZENECA DL-,25 SP.ADR
ASTRAZENECA DL-,25 SP.ADR/ US0463531089 /
ZEGA
2024-09-02 10:15:06 AM
|
Chg.
0.00
|
Volume |
Bid10:15:23 AM |
Ask10:15:23 AM |
Market Capitalization |
Dividend Y. |
P/E Ratio |
78.50EUR
|
0.00%
|
126 Turnover: 9,951 |
78.50Bid Size: 67 |
79.00Ask Size: 66 |
244.34 bill.EUR |
- |
- |
Business description
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Management board & Supervisory board
CEO |
Pascal Soriot |
Management board |
Aradhana Sarin, Pam Cheng, Ruud Dobber, Marc Dunoyer, David Fredrickson, Susan Galbraith, Menelas (Mene) Pangalos, Jeff Pott, Iskra Reic, Leon Wang, Sharon Barr |
Supervisory board |
Michel Demaré, Pascal Soriot, Aradhana Sarin, Philip Broadley, Euan Ashley, Deborah DiSanzo, Diana Layfield, Sheri McCoy, Tony Mok, Nazneen Rahman, Andreas Rummelt, Marcus Wallenberg |
Company calendar
CW 37 | 2024-09-09
Dividend Payment
|
CW 46 | 2024-11-12
Interim Report 3rd Quarter/9 Months
|